ArticleCell biochemistry and biophysics2026
Expression Profile and Role of the IGF2BP1-3 Genes During Human in vitro Osteogenic Differentiation.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs), including the let-7 family, have been shown to regulate osteogenic differentiation of human mesenchymal stem cells. Moreover, let-7 miRNAs were upregulated in the muscle tissue of patients who formed ectopic bone compared to patients who did not form ectopic bone after injury. Here we investigated the expression and role of the insulin-like growth factor 2 binding protein genes (IGF2BP1, IGF2BP2, and IGF2BP3), known targets of the let-7 miRNAs, during human in vitro osteogenic differentiation. Let-7a and let-7b were slightly upregulated on osteogenic differentiation day 7, downregulated on day 14, and slightly upregulated or unchanged on days 21 and 28. Let-7d and let-7f were upregulated on days 7, 14, 21, and 28. IGF2BP1 and IGF2BP2 were mildly modulated or unchanged on days 7, 21, and 28, and significantly downregulated on day 14, whereas IGF2BP3 was slightly upregulated on day 7 and slightly downregulated on days 14, 21, and 28. Following IGF2BP1 knockdown (KD), ALPL was upregulated on days 7 and 14, while RUNX2 and BGLAP were mildly upregulated on day 7 and mildly downregulated on day 14. We also observed more calcium deposits on IGF2BP1-KD compared to the control on osteogenic day 14. Finally, downregulation of the IGF2BP2-3 genes had no major effects on osteogenic differentiation. Altogether, we characterized the differential expression of members from the let-7-IGF2BP axis during human in vitro osteogenic differentiation and demonstrated a novel mechanistic insight where IGF2BP1 may enhance the osteogenic commitment of human bone-marrow mesenchymal stem cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.